Pfizer beats earnings forecasts and targets an additional $2.5 billion in cost reductions

{
  "signal_id": "94566e25-ef4b-8c6b-f171-efe1dfadc598",
  "signal_type": "news",
  "signal_subtype": "decreases_headcount_by",
  "detected_at": "2026-08-04T11:45:51+00:00",
  "company": {
    "name": "Pfizer",
    "domain": "pfizer.com"
  },
  "data": {
    "url": "https://www.boursorama.com/bourse/actualites-amp/pfizer-depasse-les-previsions-de-benefices-et-vise-2-5-milliards-de-dollars-de-reductions-de-couts-supplementaires-cc3b11ce6d22ec582cffc847ff8c17ce",
    "title": "Pfizer beats earnings forecasts and targets an additional $2.5 billion in cost reductions - Boursorama",
    "excerpt": "Pfizer PFE.N announced better-than-expected second-quarter results on Tuesday, driven by strong demand for the anticoagulant Eliquis, and unveiled plans to achieve an additional $2.5 billion in savings through its ongoing cost-cutting efforts. Pfizer said these additional savings, expected to be realized between 2027 and 2029, will build on existing cost-reduction measures, as the company seeks to offset declining COVID-19 related revenue and restore sustainable growth. The company is also relying on new drugs to reduce its dependence on its aging flagship medicines, while investors are watching for signs that its $10 billion acquisition of Metsera could help it gain a significant position in the rapidly growing obesity market. Pfizer said it expects to return to stronger growth after 2028. CEO Albert Bourla expressed optimism, stating that “the products launched and acquired by the company have performed well… and our obesity program is progressing with significant momentum”. Revenue from acquired products increased by 25% on an operational basis during the quarter. Eliquis sales grew by 19% on an operational basis, driven by higher net prices in the United States due to reduced rebates and a favorable channel mix, as well as stronger demand in global markets. Eliquis sales, which Pfizer markets in partnership with Bristol Myers Squibb BMY.N, amounted to $2.43 billion during...",
    "summary": "Pfizer plans to achieve an additional $2.5 billion in cost reductions between 2027 and 2029 through its ongoing cost-cutting efforts.",
    "planning": true,
    "image_url": "https://www.boursorama.com/bundles/boursoramaui/images/news/trading-news-7.jpg",
    "confidence": 0.9,
    "published_at": "2026-08-04T11:45:51Z",
    "article_sentence": "Pfizer PFE.N announced better-than-expected second-quarter results on Tuesday, driven by strong demand for the anticoagulant Eliquis, and unveiled plans to achieve an additional $2.5 billion in savings through its ongoing cost-cutting efforts.",
    "amount_normalized": 2500000000
  }
}

curl https://signals.autobound.ai/v1/signals/94566e25-ef4b-8c6b-f171-efe1dfadc598 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"pfizer.com","limit":20}'